48North Cannabis Corp. to Host 2021 Third Quarter Financial Results Conference Call on Monday, May 31, 2021 at 8:30 A.M. (ET)
May 21, 2021 17:23 ET | 48North Cannabis Corp.
TORONTO, May 21, 2021 (GLOBE NEWSWIRE) -- 48North Cannabis Corp. ("48North" or the "Company") (TSXV: NRTH), a brand-led, vertically integrated Licensed Producer focused on manufacturing an expansive...
20170420-GTGold200.jpg
GT Gold Reports Third Quarter 2020 Financial Results
November 27, 2020 17:48 ET | GT Gold Corp
VANCOUVER, British Columbia, Nov. 27, 2020 (GLOBE NEWSWIRE) -- GT Gold Corp. (TSX-V:GTT ; OTCQX:GTGDF) (the “Company” or “GT Gold”) reports its unaudited financial results for the quarter ended...
greylogo.png
VitalHub Reports an Increase in Revenue of 33% and an Increase of Annual Contract Value of 143% over the prior year.
November 24, 2020 20:24 ET | Vitalhub Corp.
TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) announced today it has filed its Interim Condensed Consolidated Financial Statements and...
Pharmagest_Logo_2020_EN.png
Pharmagest Interactive: 2020 third-quarter revenue: up 25.70% to €44.34m
November 18, 2020 12:00 ET | PHARMAGEST INTERACTIVE
Villers-lès-Nancy, 18 November 2020 - 6:00 p.m. (CET)PRESS RELEASE Pharmagest Group – 2020 third-quarter revenue: up 25.70% to €44.34m Strong recovery in business since June: Like-for-like...
PHARMAGEST INTERACTIVE : Forte croissance du chiffre d’affaires du 3ème trimestre 2020 : +25,70% à 44,34 M€
November 18, 2020 12:00 ET | PHARMAGEST INTERACTIVE
Villers-lès-Nancy, le 18 novembre 2020 - 18h00 (CETCOMMUNIQUE DE PRESSE Forte croissance du chiffre d’affaires du 3ème trimestre 2020 : +25,70% à 44,34 M€ Forte reprise de l’activité commerciale...
BioSyent logo.png
BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020
November 17, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
INNATEvertnoir.png
Innate Pharma Reports Third Quarter 2020 Financial Results and Business Update
November 17, 2020 01:00 ET | INNATE PHARMA
Lacutamab granted PRIME designation in Sézary Syndrome by the European Medicines AgencyMonalizumab Phase 3 study initiated, triggering $50 million milestone paymentCash position of €163.6 million1 as...
INNATEvertnoir.png
Innate Pharma reports third quarter 2020 financial results and business update
November 17, 2020 01:00 ET | INNATE PHARMA
Lacutamab granted PRIME designation in Sézary Syndrome by the European Medicines AgencyMonalizumab Phase 3 study initiated, triggering $50 million milestone paymentCash position of €163.6 million1 as...
INNATEvertnoir.png
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au troisième trimestre 2020
November 17, 2020 01:00 ET | INNATE PHARMA
Lacutamab a reçu le statut « PRIME » de l’Agence Européenne du Médicament dans le syndrome de SézaryLe démarrage de la Phase 3 de monalizumab déclenche un paiement d’étape de 50 millions de dollars...
2018-BRAND-LEGACY.png
Legacy Housing Corporation Reports 2020 Third Quarter Results
November 16, 2020 19:15 ET | Legacy Housing Corporation
BEDFORD, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (NASDAQ: LEGH) today announced its financial results for the third quarter ended September 30, 2020. Financial...